methylprednisolone + methylprednisolone
Phase 1Withdrawn 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Therapeutic Equivalency
Conditions
Therapeutic Equivalency
Trial Timeline
Jan 1, 2012 → Feb 20, 2012
NCT ID
NCT01405131About methylprednisolone + methylprednisolone
methylprednisolone + methylprednisolone is a phase 1 stage product being developed by Pfizer for Therapeutic Equivalency. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01405131. Target conditions include Therapeutic Equivalency.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01405131 | Phase 1 | Withdrawn |
| NCT01405157 | Phase 1 | Withdrawn |
| NCT01405170 | Phase 1 | Withdrawn |
Competing Products
11 competing products in Therapeutic Equivalency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) + Rivaroxaban (Xarelto, BAY59-7939) | Johnson & Johnson | Phase 1 | 33 |
| Remimazolam Tosilate for Injection + Remimazolam Tosilate for Injection | Jiangsu Hengrui Medicine | Approved | 85 |
| Amifostine + Carboplatin + Paclitaxel | AstraZeneca | Phase 2 | 52 |
| methylprednisolone + methylprednisolone | Pfizer | Phase 1 | 32 |
| etynodiol diacetate + etynodiol diacetate | Pfizer | Phase 1 | 32 |
| methylprednisolone + methylprednisolone | Pfizer | Phase 1 | 32 |
| Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine | Pfizer | Phase 1 | 32 |
| BAY98-7111 + Naproxen Sodium (Aleve, BAYH6689) + Diphenhydramine HCl + BAY98-7111 | Bayer | Phase 1 | 30 |
| Pravastatin + Pravastatin | Viatris | Phase 1 | 30 |
| Pravastatin + Pravastatin | Viatris | Phase 1 | 30 |
| Raxibacumab | Emergent BioSolutions | Phase 2/3 | 57 |